Impressive recent work has shown that reducing levels of TIA1 or ataxin-2 delays disease progression in models for Alzheimer's disease (AD) or ALS, respectively (Apicco et al., 2018; Becker et al., 2017), further supporting the importance of RBPs in neurodegenerative diseases. This evidence concerns the gene TIA1 and amyotrophic lateral sclerosis.